X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with TIMKEN INDIA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TIMKEN INDIA - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

TIMKEN INDIA 
   Change

Tata Timken Ltd. (TTL), the country`s second largest ball-bearing (tapered and cartridge tapered) manufacturer after SKF, has become an 80% subsidiary of the $2.4 billion family controlled Timken USA, after buying out the Tata`s 40% stake in the comp... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TIMKEN INDIA INDOCO REMEDIES/
TIMKEN INDIA
 
P/E (TTM) x 34.9 63.7 54.7% View Chart
P/BV x 4.1 10.0 41.4% View Chart
Dividend Yield % 0.5 0.1 497.3%  

Financials

 INDOCO REMEDIES   TIMKEN INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
TIMKEN INDIA
Mar-17
INDOCO REMEDIES/
TIMKEN INDIA
5-Yr Chart
Click to enlarge
High Rs360675 53.4%   
Low Rs249435 57.3%   
Sales per share (Unadj.) Rs119.0155.3 76.6%  
Earnings per share (Unadj.) Rs8.414.3 58.5%  
Cash flow per share (Unadj.) Rs15.218.5 82.1%  
Dividends per share (Unadj.) Rs1.601.00 160.0%  
Dividend yield (eoy) %0.50.2 291.4%  
Book value per share (Unadj.) Rs70.790.9 77.8%  
Shares outstanding (eoy) m92.1568.00 135.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.6 71.7%   
Avg P/E ratio x36.438.8 93.8%  
P/CF ratio (eoy) x20.029.9 66.8%  
Price / Book Value ratio x4.36.1 70.6%  
Dividend payout %19.17.0 273.5%   
Avg Mkt Cap Rs m28,08337,743 74.4%   
No. of employees `0006.00.7 841.8%   
Total wages/salary Rs m2,167737 293.9%   
Avg. sales/employee Rs Th1,817.014,730.5 12.3%   
Avg. wages/employee Rs Th359.01,028.2 34.9%   
Avg. net profit/employee Rs Th127.71,355.6 9.4%   
INCOME DATA
Net Sales Rs m10,96810,562 103.8%  
Other income Rs m4099 40.0%   
Total revenues Rs m11,00710,661 103.2%   
Gross profit Rs m1,5651,580 99.0%  
Depreciation Rs m633289 219.0%   
Interest Rs m628 739.3%   
Profit before tax Rs m9091,382 65.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139410 33.8%   
Profit after tax Rs m771972 79.3%  
Gross profit margin %14.315.0 95.4%  
Effective tax rate %15.329.7 51.4%   
Net profit margin %7.09.2 76.4%  
BALANCE SHEET DATA
Current assets Rs m5,7255,494 104.2%   
Current liabilities Rs m5,4542,331 234.0%   
Net working cap to sales %2.529.9 8.2%  
Current ratio x1.02.4 44.5%  
Inventory Days Days6265 95.7%  
Debtors Days Days7266 108.1%  
Net fixed assets Rs m5,3072,887 183.8%   
Share capital Rs m184680 27.1%   
"Free" reserves Rs m6,3315,499 115.1%   
Net worth Rs m6,5166,179 105.5%   
Long term debt Rs m1,3230-   
Total assets Rs m11,9708,727 137.2%  
Interest coverage x15.6165.5 9.5%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.91.2 75.7%   
Return on assets %7.011.2 61.9%  
Return on equity %11.815.7 75.2%  
Return on capital %12.422.5 55.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5073,293 136.9%   
Fx outflow Rs m1,1412,491 45.8%   
Net fx Rs m3,366802 419.6%   
CASH FLOW
From Operations Rs m8861,642 54.0%  
From Investments Rs m-1,706-1,251 136.3%  
From Financial Activity Rs m1,316-47 -2,793.4%  
Net Cashflow Rs m497344 144.4%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 12.5 5.5 227.3%  
FIIs % 6.0 6.4 93.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 13.2 169.7%  
Shareholders   12,805 49,890 25.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   KITEX GARMENTS  COX & KINGS  COMMEX TECHNOLOGY  THOMAS COOK INDIA  MIC ELECTRONICS  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jan 23, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS